

### Non-Imposed PASS Protocols

### A new option with Scientific Advice



Presented by Jane Moseley on 13 March 2015 Scientific officer/Scientific Advice





### **Overview**

- High level view of proposal and rationale
- Scientific advice working party overview
- Next steps





### New approach

- Opening requests for EMA scientific advice to protocols for nonimposed Post Authorisation Safety Studies (PASS)
- Building in PRAC review in the process

Imposed PASS protocols – respect formal procedures under articles 107n–q Dir 2001/83/EC as amended





### Added value of scientific advice approach

- Will have strong PRAC–SAWP interaction
- Benefits / opportunities / strategic interest
  - Lifecycle approach
  - Integration of Safety, Quality, Efficacy and Pharmacovigilance planning
  - Optimise product development
  - Bridge observational/non-observational studies



3rd Industry Platform Meeting - Pharmacovigilance Legislation



### Added value of scientific advice approach

- Will facilitate potential efficiency gains across the system whilst maintaining adequate oversight
- More intensive interaction with the MAH (within the procedure) than what happens at PRAC
- Allows additional experts, Follow up advices
- Early and/or late protocol development
- Pre and/or post-authorisation





### **PASS** categories in focus

• Category3: 'Required to investigate a safety concern in the RMP or to evaluate the effectiveness of risk'

 Category 4: Other studies conducted by MAH which may provide safety information but are not considered to be of significant importance in investigating a safety concern or the effectiveness of risk minimisation activities



3rd Industry Platform Meeting - Pharmacovigilance Legislation



### **Final protocols**

 Final protocols for category 3 studies required by the PRAC will continue to be submitted to PRAC





### **Procedural elements**

- Scientific advice is voluntary, fees levied
- Proposed procedure systematically involves PRAC for protocols submitted to Scientific Advice
- PRAC formally considers and adopts scientific advice relating to PASS
- All scientific advice documents will be available to the full PRAC.
- PRAC will be invited to comment during the procedure.




### Timing

- 40 or 70 day procedures
- Briefing document +Letter of intent submitted according to published Scientific Advice deadlines
- Allows possible presubmission TC
- Lead time (Submission to start of procedure)
  - No presubmission 3 weeks
  - With presubmission 7 weeks





# Presubmission and 70 day procedure with committee interaction





### **Information on SAWP**

- Submission by letter of intent to <u>scientificadvice@EMA.europa.eu</u> with briefing document and annexes
- Published timelines
- Briefing document template
- Contact point <u>scientificadvice@ema.europa.eu</u>





### Scientific Advice Working Party (SAWP)

NEW- 2 joint PRAC –SAWP members with pharmepi expertise Multidisciplinary expert group Scientific secretariat EU Regulatory network/experts Working parties and Committees Patient & health care professional organisations HTAS Other regulators Additional external experts



### Pilot

- 1. Pilot of 12 months for the new procedure to be undertaken
- 2. SA PASS can be submitted Q3
- 3. Joint SAWP PRAC membership (based on study design expertise)
- 4. Procedural details to be elaborated further
- 5. Further communications/guidance to be made available shortly





### Conclusion

New option for advice on PASS protocols

### Benefits / opportunities Strategic interest and efficiency gains





## Thank you for your attention

### Further information

Dr Jane Moseley, Scientific Officer, EMA scientific advice Jane.moseley@ema.europa.eu Tel +44 (0)20 3660 7149

#### **European Medicines Agency**

30 Churchill Place • Canary Wharf • London E14 5EU • United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact



